This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Alessandra Petrucco, MD; Paolo Bordin, MD; Paolo G. Da Col, MD; Maurizio Fonda, MD; Luigi Cattin, MD
University of Trieste Trieste, Italy

JAMA. 1995;273(7):520-521.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.

—Dr Agishi¹ discusses the evidence that anaphylactoid reactions could occur during low-density lipoprotein (LDL) apheresis performed with the dextran sulfate— cellulose (DSC) adsorption columns² in patients taking angiotensin converting enzyme (ACE) inhibitors.³ This adverse reaction is triggered by the entrapment of the Hageman factor, high-molecular-weight kininogen, and prekallikrein into the DSC column, leading to kallikrein activation and bradykinin generation. Bradykinin is usually inactivated rapidly by kinases I and II,³ which are identical to ACE and are inhibited by ACE inhibitors. Therefore, increased generation and decreased catabolism of bradykinin may explain this adverse reaction during the LDL apheresis.

Recently, we observed a case of hypotension in a patient treated with an ACE inhibitor during an LDL-apheretic procedure without the DSC column (sham apheresis). After obtaining informed consent, we routinely perform sham apheresis in candidates for chronic LDL apheresis to check its feasibility (eg, adequate . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?